癌症研究
细胞毒性T细胞
T细胞
医学
程序性细胞死亡1
免疫疗法
CD8型
过继性细胞移植
细胞凋亡
细胞疗法
免疫学
嵌合抗原受体
细胞
颗粒酶B
程序性细胞死亡
作者
Jiacheng Chu,Chenya Wang,Qingle Ma,Huaxing Dai,Jialu Xu,Edikan A. Ogunnaike,Fei Peng,Xiaolin Shi,Chao Wang
标识
DOI:10.1016/j.jcyt.2021.08.004
摘要
Abstract Background aims Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown great success in clinical trials. Programmed cell death 1 (PD-1)-expressing TILs show high specificity to autologous tumor cells. However, limited therapeutic efficiency is observed as a result of the tumor immune microenvironment (TIME). Methods Coupling PD-1+ ex vivo-derived TILs with a monoclonal antibody against anti-PD-1 (aPD-1) reinvigorated the anti-tumor response of TILs against solid tumor without altering their high tumor targeting ability. Results Using a melanoma-bearing mouse model, PD-1+ TILs blocked with aPD-1 (PD-1+ TILs-aPD-1) exhibited a high capability for tumor targeting as well as improved anti-tumor response in TIME. Tumor growth was substantially delayed in the mice treated with PD-1+ TILs-aPD-1. Conclusions The strategy utilizing TIL therapy coupled with immune checkpoint antibodies may extend to other therapeutic targets of ACT.
科研通智能强力驱动
Strongly Powered by AbleSci AI